The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports
Pharma Looks To Improve Potential Psychedelic Stroke Drug
Can a psychedelic compound help you heal after a stroke? This biopharmaceutical company hopes it can and plans to start Phase 1 trials this September.Three Analysts Like Healthcare Co.'s Upside
It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care.New Drug Is Shown to Help Stopped or Reduced Bile Flow
Research Report
Albireo Pharma Inc.'s positive Phase 3 trial results indicate the medication would afford patients clinical and quality of life benefits, noted an H.C. Wainwright & Co. report.
New DMD Drug Yields 'Compelling' Data
Research Report
A statistical reanalysis of trial results from Sarepta Therapeutics Inc. shows improved patient function, noted an Oppenheimer report.
Amended Agreement to Benefit Two Biotech Firms
Research Report
In the new arrangement between Beam Therapeutics Inc. and Verve Therapeutics Inc. each of the companies grants the other an exclusive license, one to a base editing target, the other to a gene delivery technology, noted a Wedbush report.
Co. Makes Financing Deals Around Two of Its Approved Drugs
Research Report
The agreements include milestone payments based on future revenue from sales of the biopharma Blueprint Medicines Corp.'s therapies, noted a Wedbush report.
Strong Data Suggest FDA Will Approve New Lymphoma Drug
Research Report
A green light is expected for the treatment after its developers submit a biologics license application for it, planned for H2/22, noted an H.C. Wainwright & Co. report.
The FDA Is Expected to Approve New Narcolepsy Drug
Research Report
Avadel Pharmaceuticals Plc., the biopharma company behind this treatment, is currently undervalued and rated Outperform, noted an Oppenheimer report.
Trial of New Alzheimer's Drug Slated for Early 2023
Research Report
The biotech behind this product candidate differentiates itself from competitors with its approach to developing selective antibody therapies, noted an Argus Research Co. report.
Chen's Top Picks for Q3
Need to know where to go in these turbulent times? Asset manager Chen Lin has some ideas with his top picks for the third quarter.BioNTech and Pfizer Secure $3.2B Vaccine Order from US Govt.
Shares of BioNTech SE traded 5% higher after the company together with its partner Pfizer Inc. reported that the two firms have agreed to provide 105 million 30 µg, 10 µg and 3 µg new doses of the SARS-Co-V2 vaccine to the U.S. government in a contract valued at $3.2 billion. The agreement includes a provision allowing the U.S. government to purchase up to an additional 195 million doses, which if exercised would increase the grand total to 300 million doses.New Alzheimer's Drug Shows Promise as Monotherapy
Research Report
Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report.
Small Cap Joins With Japan Pharma to Advance Next Generation Cancer Treatment
Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates.EU Biopharma Co. Makes $247M Bid for US Oncology Co.
Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share.Approval Likely of New Gel for Skin Condition, Analyst Says
Research Report
The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report.
Gene Therapy Co. Releases Data From Huntington's Study
Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial.Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial
Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial.New Positive Data Seem to Support Drug Label Expansion
Research Report
Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report.
Results of Dermatitis Clinical Trial Due This Summer
Research Report
Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report.
New Drug for Heart Failure on Path to Approval, Analyst Says
Research Report
The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.
NFL Player Teams With Biopharma Co. to Help SCD Patients
Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease.Dispute Between Biopharma Cos. To Be Resolved by Sept. 30
Research Report
The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report.
Biotech Co. Advances 3 New Clinical Stage Assets
Research Report
Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report.
Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results
Optinose Inc. shares traded 40% higher after the company reported positive top-line data from its Phase 3 ReOpen2 Trial of XHANCE for use in treating chronic sinusitis without nasal polyps.Biopharma Co.'s New Diabetes Drug Candidate Shows Promise
Research Report
Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models.